EN
DexCom (DXCM) Stock Price Trails Stronger Q3 Earnings Momentum
Dexcom just reported Q3 2026 results with a clear beat on the key factor in diabetes technology profitability, while the stock moved only 3% higher to about US$82 in the first full session after the release. Revenue came in at US$1.34b and net income reached US$275.1m, but the main story is margin strength that supports those earnings. That restrained share price move suggests more cautious sentiment than the earnings outcome, which showed a business converting continuous glucose monitoring demand into solid cash flow and sturdier economics.
Like the margin story at DexCom but want more choices that pair strong profitability with disciplined balance sheets? Check out our screener of list of solid balance sheet and fundamentals stocks (25 results).
Q3 2026 Earnings Summary
- Revenue (Q3 2026 vs Q3 2025): US$1,344.5m vs. US$1,209.3m (up 11.2%)
- Net Income (Q3 2026 vs Q3 2025): US$275.1m vs. US$283.8m (down 3.1%)
- Basic EPS (Q3 2026 vs Q3 2025): US$0.73 vs. US$0.73 (broadly flat with 1.2% growth)
- Gross Margin (Q3 2026 vs Q3 2025): 65.1% vs. roughly 61.3% (up about 3.8 percentage points, reflecting stronger profitability on each revenue dollar)
Dexcom bull story: scale, margins and guidance under the microscope
Optimists argue Dexcom can keep layering scale on top of richer economics, turning CGM demand into a sturdier business model.
"GAAP operating income of $318.3 million or 24.3% of revenue, an increase of 590 basis points compared to the second quarter of 2025. Non-GAAP operating income* of $328.3 million or 25.1% of reported revenue, an increase of 590 basis points compared to the second quarter of 2025."
Q3 keeps that story intact. Operating margin reached 25.3% on 11% organic sales growth and gross margin of 65.1%. Management lifted full year revenue, operating margin and adjusted EBITDA margin targets. Free cash flow above US$900m year to date and US$1.8b of cash back up that profitability trend.
Testing the Dexcom bear case on growth risks
On the cautious side, critics focus on whether Dexcom can actually deliver the multi year expansion embedded in guidance without stumbling.
"Dexcom is raising the midpoint of fiscal year 2026 Revenue guidance and increasing fiscal year 2026 guidance for Non-GAAP Gross Profit Margin, Non-GAAP Operating Margin, and Adjusted EBITDA Margin to the following levels:"
Q3 results move this concern but do not remove it. Revenue advanced 11% organically, yet international growth slowed to 5% while the United States grew 14%. Margins already sit near the updated full year targets, helped by manufacturing and freight gains, which leaves less room if reimbursement, competition or new facility ramp costs bite later.
Not everyone reads the same price the same way. → See the higher figure this Narrative lands on, and how it gets there.
Hunt For Mispriced Earnings Power
DexCom recently highlighted how strong fundamentals can diverge from a muted share price for a time. The real opportunity lies in assessing stocks that could be undervalued before any disconnect between business performance and valuation narrows.
- Company 1 - 38% below our estimate - expand a new manufacturing and supply chain build while shifting more sales into higher margin film and service channels.
- Company 2 - 29% below our estimate - grow a low cost digital bank that keeps adding customers and lifting monthly revenue per active account.
- Company 3 - 21% below our estimate - add higher value optical and packaging programs as new capacity comes online for data center and complex hardware customers.
That is three of the list. See every one of the 29 undervalued companies on it →
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com